Adacel Market Report 2026

Adacel Market Overview

• The Adacel market growth in the historic period has been driven by established tdap vaccination schedules, recurring pertussis outbreaks • Market expansion is supported by growing adult immunization coverage, expansion of booster dose recommendations • Growth Driver: The Global Trend In Children's Vaccination And Its Effect On Adacel • Market Trend: Adacel Vaccine Expansion Enhancing Protection For Broader Age Groups And Public Health • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Adacel Market?

Adacel refers to a vaccine that provides protection against tetanus, diphtheria, and pertussis (whooping cough). It is commonly given as a booster shot to individuals aged 10 and older. Adacel stimulates the immune system to produce antibodies against tetanus, diphtheria, and pertussis toxins without causing the disease. It uses inactivated toxins (toxoids) and purified antigens to trigger long-lasting immunity. The main types of vaccines in the adacel market are Tdap vaccines and combination vaccines. Tdap vaccines refer to a combination vaccine that protects against tetanus, diphtheria, and pertussis (whooping cough). The various clinical indications include pertussis (whooping cough), diphtheria, and tetanus, and different age groups including adult, geriatric, and pediatric. The distribution channels including direct tenders, pharmacies, and online pharmacies, and several end users covered hospitals, clinics, and public health programs.

What Is The Adacel Market Growth Forecast?

The growth in the forecast period can be attributed to growing adult immunization coverage, expansion of booster dose recommendations, rising healthcare awareness, government supported vaccination drives, improved vaccine access channels. Major trends in the forecast period include sustained demand for adolescent and adult booster vaccines, rising focus on pertussis prevention, expansion of public immunization programs, improved awareness of lifelong vaccination needs, increased use in preventive healthcare strategies.

Global Adacel Market Segmentation

1) By Vaccine Type: Tdap Vaccines, Combination Vaccines 2) By Clinical Indication: Pertussis (Whooping Cough), Diphtheria, Tetanus 3) By Age Group: Adult, Geriatric, Pediatric 4) By End User: Hospitals, Clinics, Public Health Programs

What Is The Driver Of The Adacel Market?

The rise in children's vaccination is expected to propel the growth of the adacel market going forward. Children's vaccination refers to the process of giving vaccines to children to protect them from various infectious diseases. The rise in children's vaccination can be attributed to increased awareness, better access to healthcare, government vaccination programs, and advancements in vaccine development, all aimed at preventing childhood diseases and improving public health. Adacel is beneficial for children's vaccination as it helps protect against three serious diseases diphtheria, tetanus, and pertussis (whooping cough) with a single shot, reducing the risk of these infections in young children. For instance, in July 2024, the Pan American Health Organization, a US-based health agency, reported that global childhood immunization coverage stalled in 2023, leaving 2.7 million additional children under-vaccinated compared to pre-pandemic levels. Therefore, the rise in children's vaccination is driving the adacel industry.

Key Players In The Global Adacel Market

Major companies operating in the adacel market are Sanofi Pasteur

Global Adacel Market Trends and Insights

Major companies operating in adacel market are focusing on expanded age indications to broaden the vaccine's use across a wider range of age groups, improving public health protection and increasing market reach. Adacel helps expanded age populations by providing crucial protection against tetanus, diphtheria, and pertussis, which are particularly dangerous in older adults due to the increased risk of complications, reduced immunity over time, and potential for severe outcomes from these diseases, thus offering a booster shot to help maintain immunity and reduce the likelihood of infection in this vulnerable group. For instance, in January 2023, Sanofi Pasteur Limited, a France-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) in the United States for the use of Adacel during the third trimester of pregnancy. This approval aims to help protect infants younger than two months of age against pertussis. This innovative approach enhances vaccine efficacy, expands accessibility, and improves patient safety, ultimately contributing to global public health efforts to prevent infectious diseases. Adacel is a Tdap vaccine designed for active booster immunization against tetanus, diphtheria, and pertussis, specifically targeting individuals aged 10 to 64 years.

What Are Latest Mergers And Acquisitions In The Adacel Market?

In March 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, partnered with Sanofi Healthcare India Private Limited. The collaboration aims to improve access to Adacel across India, facilitating the vaccine's availability in both urban and rural healthcare settings. This is particularly important given the need for widespread immunization to prevent outbreaks of pertussis, especially in vulnerable populations like infants and pregnant women. Sanofi Healthcare India Private Limited is an India-based biopharmaceutical company specializing in developing vaccines, including Adacel.

Regional Insights

North America was the largest region in the adacel market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Adacel Market?

The adacel market consists of sales of single-dose prefilled syringes and multi-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Adacel Market Report 2026?

The adacel market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the adacel industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.